Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus capecitabine and cisplatin versus placebo plus capecitabine and cisplatin as first-line therapy for advanced gastric cancer
2007-000175-42Phase 3Completed
- Sponsor
- Roche
- Start
- May 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Bevacizumab + capecitabine + cisplatin with Placebo + capecitabine + cisplatin (2 arms). Primary endpoint: overall survival. Started May 2007; status: completed.
02
Drugs
bevacizumabcapecitabinecisplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2007-000175-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000175-42.